Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD3 monovalent Fab fragment
- Development stage
- Preclinical
- Lead developer
- University of Missouri-Columbia
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-CD3 monovalent Fab fragment (Mono-Fab) is an experimental immunotherapeutic agent designed to enhance T cell responses against tumors. Unlike traditional bivalent anti-CD3 antibodies that can cause systemic, non-specific T cell activation and cytokine release syndrome, these monovalent fragments bind to the CD3 complex and mimic the TCR-induced conformational change (CD3Δc). This 'co-potentiation' mechanism lowers the threshold for T cell activation specifically when the T cell receptor (TCR) is engaged with weak tumor-associated antigens (TAAs), without stimulating non-engaged T cells. Developed by researchers at the University of Missouri-Columbia, this approach aims to improve the efficacy of the endogenous T cell repertoire against poorly immunogenic tumors such as melanoma.
- Other names
- CD3 Fab fragmentsCD-3 Fab fragmentsCD 3 Fab fragmentsanti-CD3 Mono-Fabsanti-CD-3 Mono-Fabsanti-CD 3 Mono-Fabs
02
Targets
CD3E (T-cell surface glycoprotein CD3 epsilon chain)
Beyond the preview
Go deeper on anti-CD3 monovalent Fab fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD3 monovalent Fab fragment.